Begin main content

Reports

We found 5749 result(s)

lanadelumab (Takhzyro)

Last Updated: September 19, 2019
Result type: Reports
Product Line: Common Drug Review
Generic Name: lanadelumab
Indications: Hereditary angioedema, prevention

  • Brand Name: Takhzyro
  • Manufacturer: Shire Pharma Canada ULC
  • Project Number: SR0618-000
  • Project Status: Active
  • Submission Type: New

ustekinumab (Stelara/Stelara I.V)

Last Updated: September 18, 2019
Result type: Reports
Product Line: Common Drug Review
Generic Name: ustekinumab
Indications: Ulcerative colitis

  • Brand Name: Stelara/Stelara I.V
  • Manufacturer: Janssen Inc.
  • Project Number: SR0627-000
  • Project Status: Active
  • Submission Type: NewIndication

vortioxetine hydrobromide (Trintellix )

Last Updated: September 18, 2019
Result type: Reports
Product Line: Common Drug Review
Generic Name: vortioxetine hydrobromide
Indications: Major depressive disorder (MDD), adults.

  • Brand Name: Trintellix
  • Manufacturer: Lundbeck Canada Inc.
  • Project Number: SR0611-000
  • Project Status: Active
  • Submission Type: New

glycopyrrolate (Cuvposa)

Last Updated: September 18, 2019
Result type: Reports
Product Line: Common Drug Review
Generic Name: glycopyrrolate
Indications: chronic severe drooling, neurologic (pediatric)

  • Brand Name: Cuvposa
  • Manufacturer: MEDEXUS Pharmaceuticals, Inc.
  • Project Number: SR0613-000
  • Project Status: Active
  • Submission Type: New

belimumab (Benlysta )

Last Updated: September 19, 2019
Result type: Reports
Product Line: Common Drug Review
Generic Name: Belimumab
Indications: systemic lupus erythematosus

  • Brand Name: Benlysta
  • Manufacturer: GlaxoSmithKline Inc.
  • Project Number: SR0616-000
  • Project Status: Active
  • Submission Type: New

onabotulinumtoxinA (Botox)

Last Updated: September 18, 2019
Result type: Reports
Product Line: Common Drug Review
Generic Name: onabotulinumtoxinA
Indications: Migraine, chronic

  • Brand Name: Botox
  • Manufacturer: Allergan Canada Inc.
  • Project Number: SR0584-000
  • Project Status: Active
  • Submission Type: Resubmission

vedolizumab (Entyvio )

Last Updated: September 19, 2019
Result type: Reports
Product Line: Common Drug Review
Generic Name: vedolizumab
Indications: Ulcerative Colitis

  • Brand Name: Entyvio
  • Manufacturer: Takeda Canada Inc.
  • Project Number: SR0635-000
  • Project Status: Pending
  • Submission Type: New